Organization | ObsEva SA

ObsEva SA Report issue

For profit Phase 2 Phase 3

Founded: Geneva Switzerland (2012)

Organization Overview

First Clinical Trial

2014

NCT02310802

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

ObsEva SA

Active Ingredients

Drugs in Phase 3 Trials (5)

elagolix (orilissa) (3 trials)

estradiol (progynon depot) (2 trials)

linzagolix (6 trials)

nolasiban (4 trials)

norethindrone (2 trials)

Drugs in Phase 2 Trials (2)

Atosiban (tractocile) (1 trial)

obe022 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Endometriosis (Phase 3)

Hemorrhage (Phase 3)

Infertility (Phase 3)

Leiomyoma (Phase 3)

Liver Diseases (Phase 1)

Menorrhagia (Phase 3)

Myofibroma (Phase 3)

Obstetric Labor, Premature (Phase 2)

Premature Birth (Phase 2)

Renal Insufficiency (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 14
# of Trial APIs: 7